Synonym
SMER3; SMER-3; SMER 3;
IUPAC/Chemical Name
9H-Indeno-[1,2-e]-[1,2,5]-oxadiazolo-[3,4-b]-pyrazin-9-one
InChi Key
SFSSAKVWCKFRHE-UHFFFAOYSA-N
InChi Code
InChI=1S/C11H4N4O2/c16-9-6-4-2-1-3-5(6)7-8(9)13-11-10(12-7)14-17-15-11/h1-4H
SMILES Code
O=C1C2=C(C3=NC4=NON=C4N=C31)C=CC=C2
Purity
>95% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Biological target:
SMER3 is a selective inhibitor of a yeast SCF family E3 ubiquitin ligase (SCFMet30) in vitro and in vivo. SMER3 induces the expression of MET genes and blocks cell proliferation. SMER3 is also an enhancer of rapamycin.
In vivo activity:
This study discovered SMER3, which regulates diverse cellular processes including transcription, cell-cycle control and immune response. SMER3 inhibited SCF(Met30) in vivo and in vitro, but not the closely related SCF(Cdc4). SMER3 also diminished binding of the F-box subunit Met30 to the SCF core complex in vivo and show evidence for SMER3 directly binding to Met30.
Reference: Nat Biotechnol. 2010 Jul;28(7):738-42. https://pubmed.ncbi.nlm.nih.gov/20581845/
|
Solvent |
mg/mL |
mM |
comments |
| Solubility |
| DMSO |
16.8 |
75.00 |
|
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.
Preparing Stock Solutions
The following data is based on the
product
molecular weight
224.18
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
Formulation protocol:
1. Aghajan M, Jonai N, Flick K, Fu F, Luo M, Cai X, Ouni I, Pierce N, Tang X, Lomenick B, Damoiseaux R, Hao R, Del Moral PM, Verma R, Li Y, Li C, Houk KN, Jung ME, Zheng N, Huang L, Deshaies RJ, Kaiser P, Huang J. Chemical genetics screen for enhancers of rapamycin identifies a specific inhibitor of an SCF family E3 ubiquitin ligase. Nat Biotechnol. 2010 Jul;28(7):738-42. doi: 10.1038/nbt.1645. Epub 2010 Jun 27. PMID: 20581845; PMCID: PMC2902569.
In vivo protocol:
1. Aghajan M, Jonai N, Flick K, Fu F, Luo M, Cai X, Ouni I, Pierce N, Tang X, Lomenick B, Damoiseaux R, Hao R, Del Moral PM, Verma R, Li Y, Li C, Houk KN, Jung ME, Zheng N, Huang L, Deshaies RJ, Kaiser P, Huang J. Chemical genetics screen for enhancers of rapamycin identifies a specific inhibitor of an SCF family E3 ubiquitin ligase. Nat Biotechnol. 2010 Jul;28(7):738-42. doi: 10.1038/nbt.1645. Epub 2010 Jun 27. PMID: 20581845; PMCID: PMC2902569.
1: Aghajan M, Jonai N, Flick K, Fu F, Luo M, Cai X, Ouni I, Pierce N, Tang X, Lomenick B, Damoiseaux R, Hao R, Del Moral PM, Verma R, Li Y, Li C, Houk KN, Jung ME, Zheng N, Huang L, Deshaies RJ, Kaiser P, Huang J. Chemical genetics screen for enhancers of rapamycin identifies a specific inhibitor of an SCF family E3 ubiquitin ligase. Nat Biotechnol. 2010 Jul;28(7):738-42. doi: 10.1038/nbt.1645. Epub 2010 Jun 27. PubMed PMID: 20581845; PubMed Central PMCID: PMC2902569.
2: Boscaro C, Carotti M, Albiero M, Trenti A, Fadini GP, Trevisi L, Sandonà D, Cignarella A, Bolego C. Non-genomic mechanisms in the estrogen regulation of glycolytic protein levels in endothelial cells. FASEB J. 2020 Sep;34(9):12768-12784. doi: 10.1096/fj.202001130R. Epub 2020 Aug 5. PMID: 32757462.
3: Hao Y, Langford TF, Moon SJ, Eller KA, Sikes HD. Screening compound libraries for H2O2-mediated cancer therapeutics using a peroxiredoxin-based sensor. Cell Chem Biol. 2022 Apr 21;29(4):625-635.e3. doi: 10.1016/j.chembiol.2021.09.003. Epub 2021 Oct 21. PMID: 34678160.
